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DOI 10.1186/s13073-015-0143-5COMMENTSeparating the microbiome from the hyperbolome
Fergus ShanahanEditorial summary
Microbiome-based therapies are moving quickly
towards the clinic, with successes including fecal
microbial transplants for recurring Clostridium difficile,
hints of new antibiotics to come, and possible new
microbial biomarkers for common complex diseases.
Can the microbiome live up to its hype?important to ignore [4]. The most important lesson from“Let us leave theories there and return to here’s here.”
– James Joyce, Finnegans Wake [1]
It has become fashionable to advise against overstating
the role of the microbiome in health and disease and to
warn of the danger of mistaking correlation for causation
[2]. Hype and hyperbole hindered science and medicine
long before any resurgence of interest in the microbiome,
and self-evident nuggets of received wisdom and skepticism
should not distract from the success stories and lessons
already generated by this field. Indeed, few areas in science
have been translated as quickly to therapeutic medicine.
Advances range from therapeutic modification of the
microbiota with probiotics, antibiotics or fecal microbial
transplantation (FMT), to the use of microbial compos-
itional changes as biomarkers of disease risk and the
exploration of the microbiota as a repository for natural
agents that could be harnessed as therapeutics [3].
From microbes to therapies
Arguably, the most important and therapeutically signifi-
cant discovery that has arisen from studying the micro-
biota is the link between Helicobacter pylori and peptic
ulcer disease, gastric cancer and some forms of gastric
lymphoma [4]. This was the result of fresh thinking
across artificial boundaries of knowledge and exposed
the folly of traditional ‘risk factor epidemiology’, which
had missed a transmissible agent in peptic ulcer diseaseCorrespondence: f.shanahan@ucc.ie
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unless otherwise stated.for many decades. The H. pylori story is not a simple
tale of infection and host response, ending with elimin-
ation of the organism. The truth is more complex, and
included the protective effects of H. pylori against reflux
and cancer of the gastro-esophageal junction. This much
we know; but the possibility that loss of H. pylori and
other ancient microbes in a modern world might predis-
pose to metabolic, immune and allergic disorders is too
this discovery was that there are some diseases, seem-
ingly complex and heterogeneous, that cannot be solved
by research focused only on the host, without due regard
for the microbial environment. It is no overstatement to
predict that other complex disorders, such as colon can-
cer and perhaps some forms of inflammatory bowel dis-
ease, might likewise have a microbial basis, although not
necessarily with a one-microbe-one-disease relationship;
consortia rather than individual microbes may affect dis-
ease risk depending on host susceptibility.
The best evidence for the therapeutic benefits of ma-
nipulating the microbiota is ancient - FMT is an old
technique that has been rediscovered and now widely
accepted for its consistent efficacy against recurring
Clostridium difficile-associated disease [5]. Regrettably,
this striking success was accompanied by overblown ex-
pectations that the same treatment might work in a di-
versity of other conditions, such as irritable bowel
syndrome, inflammatory bowel disease or even extra-
intestinal disorders. While science continues this micro-
biological experiment to determine the minimum necessary
microbiota for a therapeutic effect and the mechanisms
underlying this, and regulatory agencies struggle to catch
up, FMT is intriguing to many patients, raising concerns
about unsupervised, self-administration. Obvious safety con-
cerns include transmission of an infection, which is prevent-
able for known pathogens, and bacterial translocation in
recipients with an impaired mucosal barrier who are chal-
lenged with the intake of a huge bacterial load. In addition,
one of the lessons from FMT in experimental animals is that
immunologic, behavioral and metabolic phenotypes can be
transferred from donor to recipient. If this extrapolates
to humans, it introduces a risk of long-term adverseis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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in humans has been shown to transfer an improved meta-
bolic phenotype from lean donors to less healthy recipients,
the reverse could also be true. This implies that donor selec-
tion for FMT should not be based solely on exclusion of
transmissible infections. Meanwhile, the availability of
an artificial stool, populated with a diversity of known, well-
characterized organisms, would circumvent most of these
concerns, and is in development by several research groups.
Harnessing microbial metabolism
New microbiome-informed therapies can be anticipated
as science progresses beyond the identification of mi-
crobes linked with health or disease toward an explor-
ation of their function. Harnessing microbial metabolism
in the treatment of disease is an old strategy. For almost
a century, clinicians have relied on colonic microbial en-
zymes to release the active agent aminosalicylate from
its parent pro-drug, sulfasalazine, to treat colitis. More
recently, the specific inhibition of microbial enzymes has
been a therapeutic landmark in cancer chemotherapy
[6]. Thus, the toxicity of irinotecan (formerly known as
CPT-11), used in the treatment of colorectal and other
cancers, can be attenuated by inhibition of bacterial glu-
curonidase. Irinotecan is activated in vivo after paren-
teral administration, metabolized by glucuronidation in
the liver before excretion in bile, and then reactivated by
bacterial glucuronidase in the bowel, where it may cause
dose-limiting diarrhea. Drugs designed to selectively in-
hibit the bacterial but not the mammalian glucuronidase
conferred protection against irinotecan toxicity without
any antimicrobial effect. The prospects for other bacter-
ial enzymes that may be tractable for therapeutic benefit
are extensive and include bile salt hydrolases, which
have been manipulated experimentally to favorably influ-
ence lipid metabolism, weight gain and cholesterol levels
in the host [7].
Of course, the most direct way to alter the compos-
ition and metabolism of the microbiota is through diet-
ary changes. Anyone who has ever changed a diaper
from a breastfed baby who is being weaned to formula
feed will be aware of the influence of diet on the fecal
microbiota. Microbial diversity is a biomarker of a
healthy enteric ecosystem. In a study of the elderly, di-
minished microbial diversity followed a reduction in
dietary diversity, and the decrease in microbial diversity
correlated with poor health [8]. While some might de-
bate the directional nature of this correlation [2], the
critical conclusion is that adequate nutrition is no longer
a matter of quantity and quality, it also requires diver-
sity. In addition to the importance of dietary diversity,
microbiome science is poised to reveal a mechanistic
basis for the health benefits of specific diets, such as
high-fiber and elemental diets, because their beneficialeffects appear to be due, in part, to an alteration in bac-
terial composition and metabolism.
Microbiome science has also cast a fresh perspective
on the dual problems of diminished development of new
antimicrobials by the pharmaceutical industry and in-
creasing antibiotic resistance. First, the microbiota is an
inner biomass from which new antimicrobial agents may
be mined. Proof of principle has been established with
the discovery of a peptide bacteriocin antibiotic with a
high degree of specificity against C. difficile [9]. The
microbiota may also be a convenient if untapped re-
source to be mined for therapeutically useful bacterio-
phages. Second, while campaigns for the more judicious
use of antibiotics have had limited impact, the long-term
consequences of disturbing the microbiota with antibiotics,
particularly in early life, seems a compelling argument to
change consumers’ attitudes and reduce unnecessary use
of antibiotics. Evidence from human and animal studies
suggests that exposure to antibiotics in early life, when the
immune system is maturing, is a risk factor for later devel-
opment of several chronic disorders, including inflamma-
tory bowel disease, asthma, irritable bowel syndrome and
metabolic disorders. The message seems clear: mind your
microbes and they will mind you.
A recent conference organized by the National Institutes
of Health reported on ‘amazing progress’ and ‘the potential
for microbiome science to produce a revolution in human
health’ [10]. Is this an overstatement? The advances
already made suggest otherwise. Are those who dwell on
false dawns and unfulfilled promises in science justified in
their skepticism about the microbiome? James Joyce, a
keen student of bowel function who died from the
complications of H. pylori-related disease, said it best:
“No assuredly, they are not justified, those gloom-
pourers who grouse…” [1].
Abbreviations
FMT: Fecal microbial transplantation.
Competing interests
The author is a shareholder in a university campus company, Alimentary
Health Ltd, and directs a research center that holds collaborative grants with
Janssen Pharmaceutical Ltd, Trino Therapeutics, General Mills, the Kerry
Group, Mead Johnson Nutrition, Friesland, Cremo, Sigmoid Pharma, Second
Genome and Nutricia.
Acknowledgements
The author’s work has been supported in part by grants from Science
Foundation Ireland in the form of a center grant (Alimentary Pharmabiotic
Centre; grant numbers SFI/12/RC/2273 and 12/RC/2273).
References
1. Joyce J. Finnegans wake. London: Penguin Books; 1992.
2. Hanage WP. Microbiome science needs a healthy dose of scepticism.
Nature. 2014;512:247–8.
3. Shanahan F. The gut microbiota – a clinical perspective on lessons learned.
N Rev Gastroenterol Hepatol. 2012;9:609–14.
4. Blaser MJ. Missing microbes. New York: Henry Holt and Co; 2014.
Shanahan Genome Medicine  (2015) 7:17 Page 3 of 35. Petrof EO, Khoruts A. From stool transplants to next-generation microbiota
therapeutics. Gastroenterology. 2014;146:1573–82.
6. Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, et al. Alleviating cancer
drug toxicity by inhibiting a bacterial enzyme. Science. 2010;330:831–5.
7. Joyce SA, Macsharry J, Casey PG, Kinsella M, Murphy EF, Shanahan F, et al.
Regulation of host weight gain and lipid metabolism by bacterial bile acid
modification in the gut. Proc Natl Acad Sci U SA. 2014;111:7421–6.
8. Claesson MJ, Jeffery IB, Conde S, Power SE, O’Connor EM, Cusack S, et al.
Gut microbiota composition correlates with diet and health in the elderly.
Nature. 2012;488:178–84.
9. Rea MC, Dobson A, O’Sullivan O, Crispie F, Fouhy F, Cotter PD, et al.
Microbes and Health Sackler Colloquium: effect of broad- and narrow-
spectrum antimicrobials on Clostridium difficile and microbial diversity in a
model of the distal colon. Proc Natl Acad Sci U S A. 2011;108:4639–44.
10. Ravel J, Blaser MJ, Braun J, Brown E, Bushman FD, Chang EB, et al. Human
microbiome science: vision for the future, Behesda, MD, July 24 to 26, 2013.
Microbiome. 2014;2:1.
